Evaxion A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announced that it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc., Rahway, N.J., USA, which will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million, as well as royalties on sales.
